Comparing the B and T cell-mediated immune responses in patients with type 2 diabetes receiving mRNA or inactivated COVID-19 vaccines
Article
[키워드] acute respiratory syndrome
adverse outcome
Alpha
Anti-RBD IgG
BNT162b2
CD4
CD8
cell-mediated immune response
cellular
Clinical outcome
comparable
CoronaVac
coronavirus
coronavirus disease
COVID-19
COVID-19 patient
COVID-19 vaccine
COVID-19 vaccines
diabete
dose
Effectiveness
evaluated
first dose
healthy individual
humoral immune response
IgG antibody
immune dysfunction
Immunological memory
immunological memory response
Immunological response
inactivated
Infection
influence
initial
memory
mRNA
neutralizing antibody
neutralizing capacity
of BNT162b2
Part
Patient
platform
potential mechanism
protective immunity
RBD
receiving
Receptor binding domain
reduction in
resulting
SARS-CoV2
second dose
sera
susceptibility
T cell response
T cells
T2D
Th1
titre
Type
type 2 diabete
type 2 diabetes
vaccination
vaccinee
Vaccines
[DOI] 10.3389/fimmu.2022.1018393 PMC 바로가기
[DOI] 10.3389/fimmu.2022.1018393 PMC 바로가기